Journal of Affective Disorders
Volume 119, Issue 1 , Pages 43-51 , December 2009

The clinical effect of clomipramine in chronic idiopathic pain disorder revisited using the Spielberger State Anxiety Symptom Scale (SSASS) as outcome scale

  • Per Bech

      Affiliations

    • Psychiatric Research Unit, Frederiksborg General Hospital, Hillerød, Denmark
    • Corresponding Author InformationCorresponding author. Psychiatric Research Unit, Frederiksborg General Hospital, Dyrehavevej 48, DK-3400 Hillerød, Denmark. Tel.: +45 48293253.
    • ,
  • Lise Gormsen

      Affiliations

    • Danish Pain Research Center, Aarhus University Hospital, Aarhus, Denmark
    • ,
  • Dorte Loldrup

      Affiliations

    • Psychiatric Research Unit, Frederiksborg General Hospital, Hillerød, Denmark
    • ,
  • Marianne Lunde

      Affiliations

    • Psychiatric Research Unit, Frederiksborg General Hospital, Hillerød, Denmark

Received 21 October 2008 ,Revised 9 March 2009 ,Accepted 9 March 2009.

References 

  1. Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke MJ, Iyengar S, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum. 2004;50:2974–2984
  2. Arnold LM, Rosen A, Pritchett YL, D'Souza DN, Goldstein DJ, Iyengar S, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain. 2005;119:5–15
  3. Bech P. The Bech–Rafaelsen Melancholia Scale (MES) in clinical trials of therapies in depressive disorders: a 20-year review of its use as outcome measure. Acta Psychiatr. Scand. 2002;106:252–264
  4. Bech P. Measurement issues. In:  D'haenen H,  den Boer J,  Willner P editor. Biological Psychiatry. Chichester: John Wiley; 2002;p. 25–36
  5. Bech P. Dose–response relationship of pregabalin in patients with generalized anxiety disorder. A pooled analysis of four placebo-controlled trials. Pharmacopsychiatry. 2007;40:163–168
  6. Bech P, Jørgensen B, Jeppesen K, Loldrup D, Vanggaard T. Personality in depression: concordance between clinical assessment and questionnaires. Acta Psychiatr. Scand. 1986;74:263–268
  7. Bech P, Kastrup M, Rafaelsen OJ. Mini-compendium of rating scales for states of anxiety depression mania schizophrenia with corresponding DSM-III syndromes. Acta Psychiatr. Scand. 1986;(Suppl. 326):1–37
  8. Bech P, Jørgensen B, Nørrelund N, Loldrup D, Langemark M, Hansen HJ, et al. Pains as presentation symptoms of depression in liaison psychiatry as evidenced by outcome of clomipramine treatment. Nordic J. Psychiatry. 1989;43:291–294
  9. Bech P, Lunde M, Bech-Andersen G, Lindberg L, Martiny K. Psychiatric outcome studies (POS): does treatment help the patients? A Popperian approach to research in clinical psychiatry. Nordic J. Psychiatry. 2007;61(Suppl. 46):4–34
  10. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch. Gen. Psychiatry. 1961;4:561–571
  11. Becker N, Sjogren P, Bech P, Olsen AK, Eriksen J. Treatment outcome of chronic non-malignant pain patients managed in a Danish multidisciplinary pain centre compared to general practice: a randomised controlled trial. Pain. 2000;84:203–211
  12. Boorsboom D. Measuring the Mind. Conceptual Issues in Contemporary Psychometrics. Cambridge: Cambridge University Press; 2005;
  13. Carlsson A. The rise of neuropsychopharmacology: impact on basic and clinical neuroscience. In:  Healy D editors. The Psychopharmacologists. London: Altman; 1996;p. 51–80
  14. Carney MNP, Roth M, Garside RF. The diagnosis of depressive symptoms and prediction of ECT response. Brit. J. Psychiatry. 1965;111:659–674
  15. Child D. The Essentials of Factor Analysis. 2nd ed.. London: Cassel Educational; 1990;
  16. Claridge G. Psychobiological models and issues. In:  Strack S editors. Differentiating Normal and Abnormal Personality. 2nd ed.. New York: Springer; 2006;p. 137–164
  17. Conrad R, Schilling G, Bausch C, Nadstawek J, Wartenberg HC, Wegener I, et al. Temperament and character personality profiles and personality disorders in chronic pain patients. Pain. 2007;133:197–209
  18. den Boer JA, Westenberg HGM, Kamerbeek WDJ, Verhoeven WMA, Kahn RS. Effect of serotonin uptake inhibitors in anxiety disorders: a double-blind comparison of clomipramine and fluvoxamine. Int. Clin. Psychopharmacol. 1987;2:21–32
  19. Derogatis LR, Lipman RS, Covi L. SCL-90: an outpatient psychiatric rating scale. Preliminary report. Psychopharmacol. Bull. 1973;9:13–28
  20. Defuentes-Merillas L, Dejong GA, Schippers GM. Reliability and validity of the Dutch version of the readiness to change questionnaire. Alcohol Alcohol. 2002;37:93–99
  21. In:  Diem K,  Lentner C editor. Scientific Tables. 7th Ed.. Basel: Geigy; 1970;p. 170
  22. DUAG (Danish University Antidepressant Group). Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology. 1986;90:131–138
  23. DUAG (Danish University Antidepressant Group). Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J. Affect. Disord. 1990;18:289–299
  24. DUAG (Danish University Antidepressant Group). Clomipramine dose–effect study in patients with depression: clinical end points and pharmacokinetics,. Clin. Pharmacol. Ther. 1999;66:152–165
  25. Eberhard G, von Knorring L, Nilsson HL, Sundquist U, Björling G, Lindern H, et al. A double-blind, randomised study of clomipramine versus maprotiline in patients with idiopathic pain syndromes. Neuropsychobiology. 1988;19:25–34
  26. Ehrenwald J. Psychotherapy: Myth and Methods. New York: Grüne and Stratton; 1966;
  27. In:  Eysenck HJ,  Eysenck SBD editor. Personality Structure and Measurement. London: Routledge & Kegan Paul; 1969;
  28. Eysenck HJ, Eysenck SBD. Manual of the Eysenck Personality Questionnaire. London: Hodder and Stoughton; 1975;
  29. Fahy TJ, O'Rourke D, Brophy J, Schazmann W, Sciascia S. The Galway Study of Panic Disorder. I: clomipramine and lofepramine in DSM III-R panic disorder: a placebo controlled trial. J. Affect. Disord. 1992;25:63–75
  30. Friis-Hasché, E., Bech, P., in preparation. Comorbidity of stress, generalised anxiety and dental anxiety in the Danish general population.
  31. Goldberg DP. The Detection of Psychiatric Illness by Questionnaire. London: Oxford University Press; 1972;
  32. Goldberg DP, Gater R, Sartorius N, Ustun TB, Piccinelli M, Gureje O, et al. The validity of two versions of the GHQ in the WHO study of mental illness in general health care. Psychol. Med. 1997;27:191–197
  33. Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain. 2005;116:109–118
  34. Hamilton M. A diagnosis and rating of anxiety. Br. J. Psychiatry Spec. Pub. 1969;3:76–79
  35. Healy D. Psychopharmacology in the new medical state. In:  Healy D,  Doogan D editor. Psychotropic Drug Development. London: Chapman and Hall Medical; 1996;p. 13–40
  36. Hedges L, Olkin I. Statistical Methods for Meta-analysis. New York: Academia; 1985;
  37. In:  Jensen TS,  Wilson PR,  Rice ASC editor. Chronic Pain. London: Arnold; 2003;
  38. Loevinger J. A systematic approach for the construction and evaluation of tests of ability. Psychol. Monogr. 1947;61:285
  39. Loevinger J. Objective tests as instruments of psychological theory. Psychol. Rep. 1957;3:635–694
  40. Loldrup D, Langemark M, Hansen HJ, Olesen J, Bech P. Clomipramine and mianserin in chronic idiopathic pain syndrome. A placebo controlled study. Psychopharmacology,. 1989;99:1–7
  41. Loldrup D, Langemark M, Hansen H, Kastrup M, Jeppesen K, Bonnevie O, et al. The validity of the Melancholia Scale (MES) in predicting outcome of antidepressants in chronic idiopathic pain disorders. Eur. Psychiatr. 1991;6:119–125
  42. Maassen G. The use of positively and negatively phrased items and the fit of factor solution. Qual. Quant. 1991;25:91–101
  43. MacLeod C, Mathews A, Tata P. Attentional bias in emotional disorders. J. Abnorm. Psychol. 1986;95:15–20
  44. Mathews A, Ridgeway V, Williamson DA. Evidence for attention to threatening stimuli in depression. Behav Res Ther,. 1996;34:695–705
  45. Melzack R, Katz J, Wall PD. Pain measurements in persons in pain. In:  Melzack R,  Katz J,  Wall PD editor. Textbook of Pain. Edinburgh: Churchill Livingstone; 1994;p. 337–351London, Madrid, Melbourne, New York and Tokyo
  46. Mogg K, Mathews A, Eysenck M. Attentional bias to threat in clinical anxiety states. Cognition and Emotion,. 1992;6:149–159
  47. Mokken R. A Theory and Procedure of Scale Analysis. Paris: Mouton; 1971;
  48. Molenaer I, Debets P, Systma K, Hensker B. User's Manual MSP. A Program for the Mokken Scale Analysis for Polytomous Items (Version 3.0). Groningen: Lec Pro Gramma; 1994;
  49. Montgomery S. Clomipramine in obsessional neurosis: a placebo-controlled trial. Pharm. Med. 1980;1:189–192
  50. Pichot P. Discovery of chlorpromazine. In:  Healy D editors. The Psychopharmacologists. London: Altman; 1996;p. 1–27
  51. Sava FA, Yates BT, Lupu V, Szentagotai A, David D. Cost-effectiveness and cost-utility of cognitive therapy, rational emotive behavioural therapy, and fluoxetine in treating depression: a randomized clinical trial. J. Clin. Psychology. 2009;65:36–52
  52. Schruers K, Konig K, Luermans J, Haack MJ, Gries E. Obsessive–compulsive disorder: a critical review of therapeutic perspectives. Acta Psychiatr. Scand. 2005;111:261–271
  53. Schweizer E, Rickels K. Placebo response in generalized anxiety: its effect on the outcome of clinical trials. J. Clin. Psychiatry. 1997;58(Suppl. 11):30–38
  54. Shembalkar P, Anand P. Peripheral Neuropathies. In:  Jensen TS,  Wilson PR,  Rice ASC editor. Chronic Pain. London: Arnold; 2003;p. 367–381
  55. Spielberger C, Gorsuch R, Luskene R. STAI Manual for the State–Trait Anxiety Inventory. Palo Alto: Consulting Psychologists Press; 1970;
  56. Staats P, Doleys DM, Hekmat H, Staats A. The powerful placebo: friend of foe?. In:  Jensen TS,  Wilson PR,  Rice ASC editor. Chronic Pain. London: Arnold; 2003;p. 273–284
  57. Staats P, Hekmat H, Staats A. The psychological behaviourism theory of pain and the placebo: its principles and results of research application. In:  Clark M,  Treisman G editor. Pain and Depression. An Interdisciplinary Patients-centred Approach. Basel: Karger; 2004;p. 28–40
  58. Von Knorring L. The pathogenesis of chronic pain syndromes. Nordic J Psychiatry. 1989;43(Suppl 20):35–41
  59. Wall P. Pain. The Science of Suffering. London: Weidenfeld and Nicolson; 1999;
  60. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr. Scand. 1983;67:361–370
  61. Zissis NP, Harmoussi S, Vlaikidis N, Mitsikostas D, Thomaidis T, Georgiadis G, et al. A randomized double-blind, placebo-controlled study on venlafaxine XR in outpatients with tension-type headache. Cephalgia,. 2007;27:315–324

PII: S0165-0327(09)00108-6

doi: 10.1016/j.jad.2009.03.007

Journal of Affective Disorders
Volume 119, Issue 1 , Pages 43-51 , December 2009

Article Tools

* Image Usage & Resolution